B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). (Q53174548)

From Wikidata

Jump to navigation Jump to search

scientific article published on 15 February 2016

Language	Label	Description	Also known as
English	B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).	scientific article published on 15 February 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

phase II clinical trial

0 references

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

Emanuele Angelucci

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Francesco Merli

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Maurizio Bonfichi

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Armando Santoro

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Monica Balzarotti

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Ercole Brusamolino

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Angelo Michele Carella

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Eleonora Russo

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Angelagiovanna Congiu

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Manuel Gotti

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Stefania Massidda

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Barbara Botto

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Giorgia Annechini

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Alessandro Re

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Vittorio Ruggero Zilioli

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Flavia Salvi

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Caterina Stelitano

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Marcello Rodari

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Roberta Murru

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Massimo Magagnoli

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Antonella Anastasia

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Rita Mazza

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Laura Giordano

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

15 February 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

57

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

2375-2381

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26879066%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Enhancement of vascular progenitor potential by protein kinase A through dual induction of Flk-1 and Neuropilin-1.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentr

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Phase 1 Trial of Gemcitabine With Bortezomib in Elderly Patients With Advanced Solid Tumors

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018)

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2016.1140161

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53174548&oldid=1520979962"